Detalles de la búsqueda
1.
Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
Breast Cancer Res Treat
; 187(3): 743-758, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728523
2.
Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
Breast Cancer Res
; 22(1): 105, 2020 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33023655
3.
Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
Breast Cancer Res
; 22(1): 110, 2020 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33092601
4.
The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis.
Breast Cancer Res Treat
; 174(2): 357-363, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30603999
5.
ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.
Breast Cancer Res
; 20(1): 151, 2018 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30545388
6.
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Support Care Cancer
; 24(1): 387-394, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26081595
7.
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Histopathology
; 67(6): 880-7, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25913507
8.
Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact.
Breast J
; 20(4): 408-13, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24985529
9.
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
Breast Cancer Res Treat
; 133(3): 1115-23, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22361999
10.
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Support Care Cancer
; 20(10): 2523-30, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22252548
11.
Nurse Navigators' Views on Patient and System Factors Associated with Navigation Needs among Women with Breast Cancer.
Curr Oncol
; 28(3): 2107-2114, 2021 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34198915
12.
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Breast Cancer Res Treat
; 114(3): 579-87, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18443903
13.
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Value Health
; 12(5): 641-8, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19490562
14.
Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04.
CMAJ
; 176(3): 327-32, 2007 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-17261829
15.
Length of survival of patients with cancer in hospice: a retrospective analysis of patients treated at a major cancer center versus other practice settings.
J Palliat Med
; 10(2): 381-9, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17472510
16.
Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations.
Expert Rev Pharmacoecon Outcomes Res
; 16(2): 245-55, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26923683
17.
EXercise to prevent AnthrCycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocol.
Pilot Feasibility Stud
; 2: 44, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27965861
18.
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC).
Lung Cancer
; 49(3): 353-61, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15936846
19.
Isolated metastasis to the cerebellopontine angle secondary to breast cancer.
Can J Surg
; 52(5): E213-4, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19865565
20.
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.
Int J Womens Health
; 6: 509-21, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24876795